| Literature DB >> 35566177 |
Miao Deng1, Xuan Yun2, Shurui Ren1, Zhixing Qing2, Fenglian Luo1.
Abstract
Plant of the genus Zingiber (Zingiberaceae) have primarily distributed in subtropical and tropical Asia, South America and Africa. The species of this genus have been widely used as food and in folk with a long history for treating various diseases. Reports related to the phytochemistry and phytochemistry of Zingiber species are numerous, but articles on the summary of the genus Zingiber remain scarce. This review aims at presenting comprehensive information about the genus Zingiber and providing a reference for the future application by systematically reviewing the literature from 1981 to 2020. Currently, a total of 447 phytochemical constituents have been isolated and identified from this genus, in which volatile oils, diarylheptanoids, gingerols, flavonoids and terpenoids are the major components. Gingerols, which are the main functional components, are the spicy and aromatic ingredients in the Zingiber species. Extracts and single compounds from Zingiber plants have been discovered to possess numerous biological functions, such as anti-inflammatory, anticancer, antimicrobial, larvicidal, antioxidant and hypoglycemic activities. This review provides new insights into the ethnomedicine, phytochemistry and pharmacology of the genus Zingiber and brings to the forefront key findings on the functional components of this genus in food and pharmaceutical industries.Entities:
Keywords: Zingiberaceae; ethnomedicine; genus Zingiber; gingerols; pharmacology; phytochemistry
Mesh:
Substances:
Year: 2022 PMID: 35566177 PMCID: PMC9103766 DOI: 10.3390/molecules27092826
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1The characteristics of some Zingiber plants. ((a) Zingiber zerumbet (L.) Smith; (b) Zingiber officinale Rosc; (c) Zingiber corallinum Hance; (d) Zingiber mioga (Thunb.) Rosc; (e) Zingiber striolatum Diels).
Figure 2Flowchart of screening and choosing eligible articles.
Figure 3Chemical structures of compounds 1–106.
Figure 4Chemical structures of monoterpenes (107–182).
Figure 5Chemical structures of sesquiterpenes, diterpenes and triterpenes (183–261).
Figure 6Chemical structures of the flavonoid compounds (262–293).
Figure 7Chemical structures of the diphenylheptanes (294–320).
Figure 8Chemical structures of the gingerol analogues (321–367).
Figure 9Chemical structures of the organic acids (368–395).
Figure 10Chemical structures of the sterides and other compounds (396–447).
Pharmacological effects of Zingiber plants.
| Pharmacological Effects | Details | Extracts/Compounds | Inhibitory Concentrations/Dose | References |
|---|---|---|---|---|
|
| Inhibition of the direct binding between intercellular adhesion molecules and lymphocyte function-associated antigen-1 of the THP-1 cells | 10-gingerol | IC50: 57.6 μM | [ |
| 8-shogaol | IC50: 65.4 μM | |||
| Inhibitory effect on direct binding between sVCAM-1 and VLA-4 of THP-1 cells | 6-shogaol | IC50: 27.1 μM | ||
| Dehydro-6-gingerdione | IC50: 62.0 μM | |||
| Inhibition of the produc-tion of pro-inflammatory cytokines from LPS stim-ulated macrophages | 6-gingerol | 50 mg/kg | [ | |
| Decreased ETBF-induced colitis via inhibition of NF-κB signaling | Zerumbone | MIC: 32–48 μg/mL | [ | |
|
| Cytotoxic effect on MRC-5 | IC50: 216.99 ± 8.27 μM for 24 h | [ | |
| IC50: 159.47 ± 9.34 μM for 24 h | ||||
| Zerumbone | IC50: 117.96 ± 5.67 μM for 24 h | |||
| Cytotoxic effect on PC-3 | IC50: 53.32 ± 1.34 μM for 24 h | |||
| IC50: 77.45 ± 0.46 μM for 24 h | ||||
| Zerumbone | IC50: 30.78 ± 1.31 μM for 24 h | |||
| IC50: 86.05 μM | [ | |||
| 6-shogaol | IC50: 100.0 ± 13.1 μM | [ | ||
| 6-dehydrogingerdione | IC50: 106.4 ± 12.5 μM | |||
| 10-gingerol | IC50: 59.7 ± 8.2 μM | |||
| 3,5-dioxo-1,7-bis(3-methoxy-4-hydroxy)-phenyl-heptane | IC50: 153.5 ± 13.8 μM | |||
| Gingerenone A | IC50: 114.3 ± 14.2 μM | |||
| 3,5-diacetoxy-1-(3-methoxy-4,5-dihydroxy-phenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 86.6 ± 7.5 μM | |||
| Curcumin | IC50 | |||
| Cytotoxic effect on K562 | IC50: 35.73 ± 1.72 μM for 24 h | [ | ||
| IC50: 41.79 ± 1.18 μM for 24 h | ||||
| Zerumbone | IC50: 10.08 ± 0.61 μM | |||
| IC50: 29.67 μM | [ | |||
| 6-gingerol | IC50: 22.86 μM | [ | ||
| Gingerenone A | IC50: 33.3 ± 5.1 μM | |||
| 3,5-diacetoxy-1-(3-methoxy-4,5-dihydroxy-phenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 39.6 ± 4.8 μM | |||
| 1,5-epoxy-3-hydroxy-1-(3,4-hydroxy-5-methoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 160.3 ± 14.1 μM | |||
| Citrylidenmalonsaeure | IC50: 119.8 ± 9.9 μM | |||
| Curcumin | IC50: 30.5 ± 5.3 μM | |||
| Cytotoxic effect on A-549 | IC50: 44.88 ± 1.21 μM for 24 h | [ | ||
| IC50: 68.06 ± 1.09 μM for 24 h | ||||
| Zerumbone | IC50: 25 μM | [ | ||
| IC50: 48.87 μM | [ | |||
| 6-shogaol | IC50: 22.9 ± 2.1 μM | [ | ||
| 6-dehydrogingerdione | IC50: 81.2 ± 9.6 μM | |||
| 10-gingerol | IC50: 85.4 ± 10.2 μM | |||
| 3,5-dioxo-1,7-bis(3-methoxy-4-hydroxy)-phenyl-heptane | IC50: 248 ± 17.9 μM | |||
| Gingerenone A | IC50: 44.5 ± 5.8 μM | |||
| 3,5-diacetoxy-1-(3-methoxy-4,5-dihydroxy-phenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 96.3 ± 7.8 μM | |||
| 7-(3,4-dihydroxy-5-methoxyphenyl)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl) heptan-3-one | IC50: 83.6 ± 8.4 μM | |||
| 1,5-epoxy-3-hydroxy-1-(3,4-hydroxy-5-methoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 230.8 ± 17.9 μM | |||
| 5-[4-hydroxy-6-(4-hydroxyphenethyl) tetrahydro-2H-pyran-2-yl]-3-methoxybenzene-1,2-diol | IC50: 212.0 ± 15.2 μM | |||
| Curcumin | IC50: 58.8 ± 9.4 μM | |||
| Cytotoxic effect on H-460 | Zerumbone | IC50: 15 μM | [ | |
| Cytotoxic effect on BEL7404 | 6-shogaol | IC50: 11.8 ± 2.6 μM | [ | |
| 6-dehydrogingerdione | IC50: 115.2 ± 13.7 μM | |||
| 10-gingerol | IC50: 95.2 ± 12.2 μM | |||
| 3,5-dioxo-1,7-bis(3-methoxy-4-hydroxy)-phenyl-heptane | IC50: 49.4 ± 3.4 μM | |||
| Gingerenone A | IC50: 9.0 ± 2.3 μM | |||
| 3,5-diacetoxy-1-(3-methoxy-4,5-dihydroxy-phenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 101.9 ± 13.1 μM | |||
| 7-(3,4-dihydroxy-5-methoxyphenyl)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl) heptan-3-one | IC50: 180.6 ± 16.5 μM | |||
| 1,5-epoxy-3-hydroxy-1-(3,4-hydroxy-5-methoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 180.6 ± 12.5 μM | |||
| Curcumin | IC50: 38.2 ± 3.9 μM | |||
| Cytotoxic effect on CNE | 6-shogaol | IC50: 43.8 ± 5.0 μM | ||
| 6-dehydrogingerdione | IC50: 119.7 ± 7.9 μM | |||
| 10-gingerol | IC50: 88.1 ± 7.3 μM | |||
| 3,5-dioxo-1,7-bis(3-methoxy-4-hydroxy)-phenyl-heptane | IC50: 76.7 ± 5.4 μM | |||
| Gingerenone A | IC50: 27.7 ± 3.9 μM | |||
| 3,5-diacetoxy-1-(3-methoxy-4,5-dihydroxy-phenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 62.0 ± 10.7 μM | |||
| 7-(3,4-dihydroxy-5-methoxyphenyl)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl) heptan-3-one | IC50: 75.4 ± 6.6 μM | |||
| 1,5-epoxy-3-hydroxy-1-(3,4-hydroxy-5-methoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 174.2 ± 15.1 μM | |||
| 5-[4-hydroxy-6-(4-hydroxyphenethyl) tetrahydro-2H-pyran-2-yl]-3-methoxybenzene-1,2-diol | IC50: 247.9 ± 20.1 μM | |||
| Curcumin | IC50: 33.5 ± 10.1 μM | |||
| Cytotoxic effect on Hep-2 | Zerumbone | IC50: 15 μM | [ | |
| Anti-proliferative effect on HepG2 | Zerumbone | IC50: 3.45 ± 0.026 μg/ml | [ | |
| Cytotoxic effect on 16 human oral squamous cell carcinoma lines | Zerumbone | IC50: average 2 µM; range: 0.8–4.9 µM | ||
| Cytotoxic effect on DU145 | Zerumbone | IC50: 24 μM | [ | |
| Cytotoxic effect on HCT116 | Zerumbone | IC50: 30 ± 1.5 μM | [ | |
| Cytotoxic effect on SW620 | Zerumbone | IC50: > 46 μM | ||
| Cytotoxic effect on MCF-7 | Zerumbone | IC50: 23.0 μg/ml | [ | |
| Cytotoxic effect on MDA-MB 231 | Zerumbone | IC50: 24.3 μg/ml | ||
| Cytotoxic effect on Hela | Zerumbone | IC50: 6.4 μg/mL | ||
| 6-gingerol | IC50: 126.89 μM | [ | ||
| 6-dehydrogingerdione | IC50: 62.5 ± 4.7 μM | [ | ||
| Zingerone | IC50: 114.6 ± 9.3 μM | |||
| 10-gingerol | IC50: 52.4 ± 7.1 μM | |||
| 3,5-dioxo-1,7-bis(3-methoxy-4-hydroxy)-phenyl-heptane | IC50: 86.8 ± 10.5 μM | |||
| Gingerenone A | IC50: 15.4 ± 3.2 μM | |||
| 3,5-diacetoxy-1-(3-methoxy-4,5-dihydroxy-phenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 110.0 ± 9.8 μM | |||
| 1,7-bis(4-hydroxy-3-methoxyphenyl) heptane-3,5-diol | IC50: 191.0 ± 16.5 μM | |||
| 7-(3,4-dihydroxy-5-methoxyphenyl)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl) heptan-3-one | IC50: 133.2 ± 16.1 μM | |||
| 5-[4-hydroxy-6-(4-hydroxyphenethyl) tetrahydro-2H-pyran-2-yl]-3-methoxybenzene-1,2-diol | IC50: 231.8 ± 13.7 μM | |||
| Curcumin | IC50: 18.9 ± 2.8 μM | |||
| Inhibitory effect on epstein-barr virus | Zerumbone | IC50: 0.14 μM | [ | |
| Cytotoxic effect on KB | 6-shogaol | IC50: 7.4 ± 2.2 μM | [ | |
| 6-dehydrogingerdione | IC50: 229.5 ± 17.5 μM | |||
| 10-gingerol | IC50: 89.5 ± 8.7 μM | |||
| 3,5-dioxo-1,7-bis(3-methoxy-4-hydroxy)-phenyl-heptane | IC50: 27.7 ± 2.7 μM | |||
| Gingerenone A | IC50: 8.8 ± 2.6 μM | |||
| Curcumin | IC50: 34.7 ± 6.7 μM | |||
| 3,5-diacetoxy-1-(3-methoxy-4,5-dihydroxy-phenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC50: 75.1 ± 10.5 μM | |||
| 7-(3,4-dihydroxy-5-methoxyphenyl)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl) heptan-3-one | IC50: 90.3 ± 10.1 μM | |||
| 1,5-epoxy-3-hydroxy-1-(3,4-hydroxy-5-methoxyphenyl)-7-(4-hydroxy-3-methoxyphenyl) heptane | IC5: 78.5 ± 11.3 μM | |||
| Curcumin | IC50: 34.7 ± 6.7 μM | |||
| Cytotoxic effect on HT29 | Zerumbone | IC50: 38.8 ± 1.2 μM | [ |
IC50: the half maximal inhibitory concentration.
Figure 11The structure–activity relationship of anticancer for gingerol (a) and shogaol (b).